Rifaximin Sachet

Rifaximin Sachet
Product Description

Gut selective antibiotic
Minimal Systemic absorption
Broad Spectrum in nature

Read more Show less

Biodeal pharmaceuticals Ltd.

  • Country/Region:
    India
  • Founded:
    2005
  • On CPHI since:
    2017
  • Certificates:
    5
  • Employees:
    500 - 999
Company types
Manufacturer/Innovator
Primary activities
Contract Manufacturer
Contract Research Organisation
Nutraceuticals
Out-licensing specialist
Pharmaceutical Company (generic finished products)
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    MECHANISM OF ACTION
    Rifaximin is a non-systemic, gut-selective antibiotic that inhibits bacterial RNA synthesis by binding the beta-subunit of DNA-dependent RNA polymerase. With under 1% systemic absorption, it reaches high concentrations within the GI lumen while minimising systemic side effects and drug interactions — a favourable profile for repeated or prolonged use.

    THERAPEUTIC INDICATIONS
    1.Traveller's diarrhoea (non-invasive E. coli)
    2.Hepatic encephalopathy (reduction of recurrence)
    3.Irritable bowel syndrome with diarrhoea (IBS-D)
    4.Small intestinal bacterial overgrowth (SIBO), where approved
  • Model
    7gm sachet (400 mg / 550 mg)
  • Supplied from
    India
  • Measured In
    gram
More specifications Fewer specifications
Sales Markets
Show more Show less

Biodeal pharmaceuticals Ltd.

  • Country/Region:
    India
  • Founded:
    2005
  • On CPHI since:
    2017
  • Certificates:
    5
  • Employees:
    500 - 999
Company types
Manufacturer/Innovator
Primary activities
Contract Manufacturer
Contract Research Organisation
Nutraceuticals
Out-licensing specialist
Pharmaceutical Company (generic finished products)
View company profile

More Products from Biodeal pharmaceuticals Ltd. (5)

  • Nasal Spray Range

    Product Nasal Spray Range

    Fluticasone Furoate 27.5 mcg Fluticasone Furoate 27.5 mcg + Oxymetazoline 50 mcg Mometasone Furoate 50 mcg Azelastine Hydrochloride 140 mcg Intranasal corticosteroids, combination decongestant, and antihistamine spray — allergic & non-allergic rhinitis range
  • Injectables - FULL CARBAPENEM Range

    Product Injectables - FULL CARBAPENEM Range

    MECHANISM OF ACTION
    Carbapenems are broad-spectrum beta-lactam antibiotics that bind penicillin-binding proteins (PBPs) in the bacterial cell wall, inhibiting peptidoglycan cross-linking and causing cell lysis. Their structure confers high stability against most beta-lactamases, including many that in...
  • Midazolam Nasal Spray

    Product Midazolam Nasal Spray

    Benzodiazepine, intranasal route, seizure rescue / procedural sedation
  • Nasal Spray Range (Fluticasone Furoate / Oxymetazoline / Mometasone / Azelastine)

    Product Nasal Spray Range (Fluticasone Furoate / Oxymetazoline / Mometasone / Azelastine)

    MECHANISM OF ACTION
    This range covers two complementary drug classes used intranasally for rhinitis. Fluticasone furoate and mometasone furoate are trifluorinated/synthetic corticosteroids with high glucocorticoid receptor affinity, suppressing histamine, prostaglandins, leukotrienes and cytokines...
  • Vonoprazan Tablets

    Product Vonoprazan Tablets

    Potassium-competitive acid blocker (P-CAB); GERD, H. pylori eradication, peptic ulcer disease

Biodeal pharmaceuticals Ltd. resources (3)

  • Company Profile

    Brochure Company Profile

  • Product Portfolio

    Brochure Product Portfolio

  • Biodeal Pharmaceuticals - Company Profile

    Brochure Biodeal Pharmaceuticals - Company Profile

    Biodeal Pharmaceuticals Limited is a WHO-GMP and PIC/S certified, USFDA-compliant Contract Development and Manufacturing Organisation (CDMO) founded in 2005. Headquartered in Noida with manufacturing facilities across Himachal Pradesh, we serve 1000+ clients across 80+ countries with a portfolio of 1,000+ formulations and 100+ global regulatory registrations. 

    India's leading nasal spray CDMO. Largest innovative range globally across 20+ formulations including complex molecules. State-of-the-art nasal filling line with advanced plume geometry, particle size and spray pattern testing. Three DCGI approvals in 2024–25. Active pipeline of India-first and global-first molecules.

    Injectables: dedicated advanced sterile manufacturing facility at Paonta Sahib. 12 production lines across general injectables, broad-range carbapenems and hormone injectables.